Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Abaxis Enters Into Worldwide OEM Agreement

For a lateral flow avian influenza antigen test kit

Abaxis has entered into the production animal diagnostics marketplace with its first product, a rapid Avian influenza antigen test. This is a USDA-licensed test for Avian influenza type A nucleoprotein antigen in chickens, turkeys and ducks. The disposable, non-instrumented device, providing results in 15 minutes, can be used in the field or in a laboratory of any size.

The company claims that this is the fourth new product launched by Abaxis Animal Health this calendar year. In January, Abaxis began providing the marketplace its first lateral flow product, a rapid canine heartworm antigen test.

Martin Mulroy, vice president of sales and marketing, North American Animal Health at Abaxis, said: “Abaxis is the 2nd largest and fastest growing Animal Health diagnostics company in the world. Our reputation for innovation, quality, reliability and service in the companion animal marketplace, the equine marketplace, and the research market is unparalleled.

“Our entry into production animal diagnostics is a win for Abaxis and its shareholders, Abaxis distributors who participate in this marketplace, the production animal industry and those clinicians and laboratories serving it, and the population at large.

“This new product further extends Abaxis’ scope, building on our strong position of having worldwide rights in the field of animal health diagnostics using certain technologies pertaining to lateral flow immunoassay devices and methods.”

Michael Solomon, director of business development of North American Animal Health at Abaxis said: “We are already investigating and have made headway evaluating synergies in production animal diagnostics with our current portfolio of products, internal research and development opportunities leveraging existing Abaxis intellectual property, and other joint development ventures.”